by Matthew Johnson | Oct 26, 2023 | Estoppel, Final Written Decisions, PTAB News
By Anthony Kim*, Evan Jones, and Matt Johnson – The Patent Trial and Appeal Board held all challenged claims of IGT’s patent unpatentable as obvious over two prior art patents. Zynga Inc. v. IGT, IPR2022-00199-32. In doing so, the PTAB further held that,...
by Matthew Johnson | Oct 20, 2023 | Final Written Decisions, Prior Art Issues, PTAB News
By Hannah Mehrle and Matt Johnson – At the Inter Partes review trial, Patent Owner attempted to swear behind Petitioner’s primary prior art reference by showing that the inventors of the asserted patents had conceived of the invention before the priority date of...
by Matthew Johnson | Oct 16, 2023 | PTAB News, PTAB Trial Basics, Trial Institution
By Simon Maxwell* and Matt Johnson – On March 15, 2022, Facet Technologies, LLC (Plaintiff/Patent Owner) filed an infringement suit against LifeScan, Inc. (Defendant/Petitioner) in U.S. District Court for infringement of U.S. Patent No. 8,840,635 (the ’635...
by Matthew Johnson | Oct 10, 2023 | 325(d) issues, PTAB News, Trial Institution
By Daniel Sloan and Matt Johnson – On August 24, 2023, USPTO Director Kathi Vidal vacated a PTAB decision denying institution of inter partes review in Keysight Technologies, Inc. v. Centripetal Networks, Inc. and remanded the case for further proceedings....
by Matthew Johnson | Oct 4, 2023 | PTAB News, PTAB Trial Basics, Time Limits
By Tova Werblowsky* and Matt Johnson – Institution of an IPR is automatically barred if the “petition requesting the proceeding is filed more than 1 year after the date on which the petitioner…is served with the complaint alleging infringement of the patent.” 35...
by Kunyong Yang | Sep 28, 2023 | Pharmaceutical, PTAB News
By Raffaella Faraoni and Kunyong Yang – On August 22, 2023, the Federal Circuit issued a nonprecedential decision holding that claims directed to deuterated analogs of ruxolitinib were unpatentable as obvious. Sun Pharm. Indus., Inc. v. Incyte Corp., No....
